Eli Lilly's Antibody Reduces COVID-19 Risk by 80% in Nursing Homes
Nursing home residents who still haven't received a coronavirus vaccination can rest a little easier. Positive clinical-trial results released by Eli Lilly (NYSE: LLY) on Thursday suggest its bamlanivimab can reduce the risk of COVID-19 by 80% for nursing home residents.
Bamlanivimab is an antibody that gloms onto the spiky part of the coronavirus responsible for COVID-19. The Food and Drug Administration has authorized it as a treatment for COVID-positive patients who are at risk of a severe infection, but not affected severely enough to require hospitalization.
Image source: Getty Images.
Source Fool.com
